Artivion : CryoLife Announces Corporate Rebranding and Changes Name to Artivion - Form 8-K
January 21, 2022 at 03:13 am IST
Share
CryoLife Announces Corporate Rebranding and Changes Name to Artivion
Artivionto Host Investor & Analyst Day on March 23, 2022
ATLANTA, GA - (January 18, 2022) - CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words "aorta", "innovation", and "vision",the company'snew name and brand reflect its evolution to focus on providinginnovative technologies to surgeons who treat patients with aortic disease. In conjunction with these changes, effective January 24, 2022, the company will also changeits ticker symbol on the New York Stock Exchange to "AORT" from "CRY."
"Through a combination of legacy products and strategicacquisitions and divestitures over the last five years, we have transformed from a tissue and adhesives focused company to one with a premier portfolio of aortic products," said Pat Mackin, Chairman, President and Chief Executive Officer of Artivion. "Today marks an important milestone for our company. We look forward to embarking on our next chapter as a leader in developing simple, elegant solutions to address cardiac and vascular surgeons' most difficult clinical challenges in treating patients with aortic disease."
Artivionwill discuss its business, its strategy, and the rebrand at anInvestor & Analyst Day on March 23, 2022, in New York City.Details of the event will be provided at a later date.
About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. (Artivion) is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult clinical challenges in treating patients with aortic diseases. This
Page 1 of 2
multinational company's four major groups of products include: aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants.Artivionmarkets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com, accessible by the end of day today.
Page 2 of 2
Attachments
Original Link
Original Document
Permalink
Disclaimer
CryoLife Inc. published this content on 20 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 January 2022 21:41:48 UTC.
Artivion, Inc. is a medical device company engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease, heart valve disease, aortic aneurysms, and dissections. The Company's segments include Medical Devices and Preservation Services. The Medical Devices segment includes sales of aortic stent grafts, surgical sealants, and On-X. The Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. It has four product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include BioGlue Surgical Adhesive products. It also sells or distributes PhotoFix bovine surgical patches.
ARTIVION, INC. 
